Fig. 2.

Metastasis-specific (a) and overall (b) survival curves of breast cancer patients according to tumour subtypes. ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor type 2. Kaplan–Meier plots of patients show that ER−/HER2− had worse survival outcomes compared to other tumour subtypes. Patients with hormone receptor-negative (ER−/HER2−) tumours had shorter survival time from detection of metastatic disease to last event and from the initial diagnosis of the disease to last event (p < 0.001)